AG Magazine • Health & Nutrition
On September 17, 2026, the FDA and HHS are holding a first-of-its-kind public workshop on testosterone therapy for women — asking, in public, a question patients have been asking their doctors in private for years. [SOURCE NOT ON ALLOWLIST — editor review] Right now, in the United States, not a single testosterone product carries FDA approval for use in women. Every prescription is off-label. That gap is about to get a public airing.
Here’s the part that surprises most people: testosterone isn’t a “male hormone” that women happen to have a little of. Women produce more testosterone than estrogen across most of the lifespan, and it plays a real role in bone density, muscle maintenance, mood, and sexual desire. Yet because no company has ever won FDA approval for a female-specific formulation, millions of women reach menopause without ever hearing testosterone mentioned as an option — while the men in their lives have had access to an approved, labeled product for decades.
This piece unpacks what the FDA workshop can realistically change, what the evidence actually supports for testosterone therapy for women, and — because hormonal health isn’t a one-sex story — what’s shifting for men, too. By the end, you’ll know exactly what to ask your doctor, whatever your age or hormone profile.
Is Testosterone Therapy Approved for Women?
No. As of 2026, the FDA has not approved any testosterone product specifically for women in the United States. Every prescription is off-label — typically a fraction of a dose approved for men. The FDA’s pending workshop is examining whether a dedicated approval pathway should exist, but any resulting product is still years away.
Why Is Testosterone Therapy for Women Still Off-Label?
No pharmaceutical company has completed the large, long-term trials the FDA typically requires — trials expensive enough that manufacturers have historically judged the market too small to justify the cost. In the meantime, physicians prescribe existing men’s formulations at roughly one-tenth the dose, a workaround grounded in real research but never formally reviewed by regulators. Mayo Clinic Press notes the caution isn’t arbitrary: the concerns center on cardiovascular disease and breast cancer risk, which is exactly why off-label use should come with monitoring, not guesswork. It’s also why testosterone therapy for women is priced and covered so inconsistently — off-label drugs are rarely reimbursed the way approved ones are.
The Science Behind Testosterone and Menopause
Does Testosterone Therapy Help With Menopause Symptoms?
For one specific symptom, yes — and the evidence is unusually strong for something so rarely discussed. The foundational 2019 Global Consensus Position Statement, endorsed by more than a dozen medical societies including the Endocrine Society, concluded that the only evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women. In trials, transdermal testosterone measurably improved desire, arousal, and satisfaction compared with placebo.
What it hasn’t reliably been shown to fix is everything else it’s often marketed for — low energy, brain fog, or general “vitality.” A 2025 narrative review found the evidence for those broader uses still falls short of what regulators — or your own judgment — should require before starting a therapy.
Is Testosterone Therapy Safe for Women?
Safety is the workshop’s real subject, and the data so far is reassuring within limits. Clinicians at Cleveland Clinic note that at physiologic, monitored doses, short-term side effects are typically mild — acne, extra hair growth, minor voice changes — and reversible when caught early. What’s still missing is long-term outcome data, particularly on cardiovascular and breast health over years rather than months. That’s precisely the knowledge gap the FDA workshop was convened to confront, and precisely why every credible clinical guideline pairs testosterone therapy with routine bloodwork rather than a prescribe-and-forget approach.
None of this means testosterone therapy is risky in the way it’s sometimes portrayed online. It means the dose, the delivery method, and the follow-up schedule matter more than the headline. A monitored, physiologic dose managed by a clinician who orders follow-up labs is a fundamentally different exposure than an unmonitored compounded pellet from a storefront clinic — even though both technically fall under “testosterone therapy for women.”
It’s Not Just a Women’s Issue — Hormonal Health Cuts Both Ways
Men’s testosterone has its own regulatory story unfolding in parallel, and it’s worth knowing because the two conversations inform each other. For years, testosterone replacement therapy in men carried strong cardiovascular warning language, based largely on smaller, shorter studies. Then came TRAVERSE, a randomized, placebo-controlled trial of more than 5,200 men with documented low testosterone and either existing heart disease or high cardiovascular risk. Published in the New England Journal of Medicine, it found testosterone-replacement therapy was noninferior to placebo for major cardiovascular events — reassuring news for a therapy millions of men already use.
The lesson for both sexes is the same: testosterone therapy works best, and is safest, when it’s prescribed for a documented deficiency and monitored like the hormone therapy it is — not treated as a wellness supplement or an anti-aging shortcut. Whether you’re a 50-year-old man asking about energy and muscle, or a 55-year-old woman asking about desire and sleep, the standard should be identical: real labs, a real indication, real follow-up.
How to Talk to Your Doctor About Hormonal Health
Whatever brought you here, the conversation with your clinician goes better when you walk in prepared. A few specific moves make the biggest difference:
- Ask for the right test, not just any test. Standard panels can miss the low concentrations typical in women; request testosterone measured by LC-MS/MS rather than a standard immunoassay.
- Name the actual symptom. “Low libido” and “low energy” lead to very different conversations — and different evidence bases.
- Ask what’s monitored, not just prescribed. A responsible plan includes a recheck schedule, not a one-time prescription.
- Separate hormone therapy from anti-aging marketing. If a clinic promises testosterone will fix your metabolism, mood, and motivation all at once, that’s a sales pitch, not a diagnosis.
- Bring your family history. Cardiovascular and breast cancer history should shape the conversation from the first visit, not after a problem appears.
⚡ PRO TIP
If your clinician orders a standard immunoassay testosterone test, ask for LC-MS/MS instead. At the low concentrations typical in women — roughly 10 to 55 ng/dL after menopause, according to a 2025 clinical review — older immunoassay methods are notoriously unreliable, which means an “in range” result on the wrong test can be meaningless either way.
Reclaim Your Hormonal Health Story — One Informed Conversation at a Time
The FDA workshop won’t produce an approved product by next spring, and it shouldn’t. Good regulation is slow on purpose. But it does something valuable right now: it puts a question millions of women have asked quietly into the public record, alongside the research men’s hormonal health has already forced regulators to reckon with.
You don’t have to wait for an approval letter to get informed. Testosterone therapy for women is real medicine with a real — if narrow — evidence base, and hormonal health at any age deserves the same rigor whether you’re 35 or 75. The workshop is a starting gun, not a finish line, and the most useful thing you can do in the meantime is stop treating your own hormonal health as background noise.
Book the conversation: ask your doctor for a testosterone panel by LC-MS/MS, and pick one specific symptom to track before your next visit. That’s how this gets less confusing — one accurate test and one honest question at a time.
